CFV4L
_edited_edited_edit.png)
Latin American Projects
Hope
4
ECUADOR
Cystic fibrosis (CF) is a life-limiting genetic disease in which most patients develop exocrine pancreatic insufficiency, yet an estimated 35% of CF patients worldwide lack access to pancreatic digestive enzymes, contributing to profound disparities in survival. In Quito, Ecuador—where life expectancy for children with CF is just 9.5 years—this study evaluates the health outcomes and cost-effectiveness of providing 25 of the most at-risk pediatric patients with pancreatic enzymes and daily multivitamins at an annual cost of $1,600 per patient. By tracking growth, lung function (FEV₁), healthcare utilization, and quality of life over time, the study aims to determine whether access to basic evidence-based nutritional therapy can improve outcomes while reducing acute healthcare costs in low-resource settings.
Left: Raul Enrique Rios Mendez, Pediatric Cardiologist; Maria Eugenia Arauz Martinez, Pediatric Pulmonologist; Mark Tremblay, President and Founder of CFV4L, MaryGrace Tremblay, Vice President of CFV4L, Travis Suit, Executive Director of Piper’s Angels Foundation
Left Corporate Partner Hellmuch Barisch, Director, Evolution Nuetraceutical; Non-profit Partner, Lupita Compoy, Director, Association Mexicana de Fibrosis Quistica, Mark Tremblay, President, CFV4L, and Government Partner, Jose Luis Lezana Fernandez, MD, Medical Director at Frederico Gomez Children's Hospital
More Mornings
4
MEXICO
CFV4L, Piper’s Angels Foundation, Frederico Gomez
Children’s Hospital, Aerosol Medical Systems, Evolution Nuetracutical, and University of West Georgia have collaborated to provide basic evidenced based care to children and young adults with CF in Mexico City and evaluate its impact on the patients.
.
Children with cystic fibrosis (CF) in low-resource settings often lack access to basic, evidence-based care, contributing to dramatically reduced life expectancy, including just 23 years at Mexico City’s Federico Gómez Children’s Hospital. This study evaluates the health and cost impact of providing a comprehensive basic CF care package including: weight gainer supplements, hypertonic saline, Aerobikas, nebulizer compressors, and portable oxygen concentrators to 25 at-risk pediatric patients, at an annual cost of approximately $1,600 per child. At the 6-month mark, preliminary findings show a 6% improvement in weight, an 11% increase in FEV₁, and a projected 16% reduction in inpatient hospital days— demonstrating that modest investments in fundamental CF care can significantly improve outcomes while reducing healthcare utilization and cost.
%20-%20Baja%20Mexico.png)
